Price
$3.26-31.37%Social Signal Score
Analyst Ratings
37 analystsRevenue
$202.70M+3.16%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Samraat S. Raha
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 2,700
- Beta
- 1.61
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.95
Financials
Revenue
$202.70M+3.2%Net Income
$-43.90M-844.1%EBITDA
$-39.50M-243.1%Free Cash Flow
$-8.30M-128.6%EPS (diluted)
$-0.46-611.1%Shares Outstanding (diluted)
95.70M+40.1%Operating Expenses
$177.60MCash & Debt
$107.10MReturn of Capital
$0.00Revenue by Segment (annual)
$753.20MDividend per Share
$1.75Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $824.50M | $-365.90M | $-3.96 |
| 2024 | $837.60M | $-127.30M | $-1.41 |
| 2023 | $753.20M | $-263.30M | $-3.18 |
| 2022 | $678.40M | $-112.00M | $-1.39 |
| 2021 | $690.60M | $-27.20M | $-0.35 |
| 2020 | $557.00M | $-223.70M | $-2.99 |
| 2019 | $638.60M | $-199.50M | $-2.69 |
| 2018 | $851.10M | $4.60M | $0.06 |
| 2017 | $743.70M | $133.30M | $1.89 |
| 2016 | $728.70M | $17.40M | $0.32 |
| 2015 | $740.50M | $117.20M | $1.79 |
| 2014 | $723.10M | $80.20M | $1.12 |
| 2013 | $778.20M | $176.20M | $2.33 |
| 2012 | $613.20M | $147.20M | $1.82 |
Valuation
MYGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (10)
- Newsseekingalpha.com·17d ago·Positive
Myriad Genetics, Inc. (MYGN) Q3 2026 Earnings Call Transcript Myriad Genetics, Inc. ( MYGN ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO & Director Ben Wheeler - CFO & Principal Accounting Officer Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Kyle Boucher - TD Cowen, Research Division Presentation Operator Good day, and thank you…
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
Myriad Genetics Q3 Earnings Call Highlights Myriad Genetics NASDAQ: MYGN reported third-quarter revenue of $202.7 million, down 1% from a year earlier, as growth in cancer and mental health testing was offset by a decline in its prenatal business. The company raised its full-year revenue outlook and said early efforts to address reimbursement denials helped improve revenue per test.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will participate in three upcoming healthcare conferences. The UBS Global Healthcare Conference with a fireside chat on Tuesday, Nov. 10, 2026, at 1:15 pm ET.
View source ↗ - Newsglobenewswire.com·33d ago·Negative
… for Myriad to Sell Prenatal Health Testing Business to Labcorp SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announce they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel®, Foresight®, SneakPeek®…
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at 4:30 pm ET on Wednesday, November 4, 2026. The company's quarterly earnings will be released the same day after market close.
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026.
View source ↗ - Newsbarrons.com·82d ago·Neutral
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse. Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company's path to sustainable profitability.
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad's web…
View source ↗ - Newsgurufocus.com·106d ago·Negative
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law [url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
View source ↗ - Newsbusinesswire.com·106d ago·Negative
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.
View source ↗
Earnings
Mon, Feb 22(in 3 months)
Consensus estimate $-0.25 per share
Typical surprise +40.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.11 vs $-0.20beat
- Thu, Jul 30$-0.25 vs $-0.06miss
- Tue, May 5$-0.09 vs $-0.06miss
- Mon, Feb 23$0.04 vs $-0.02beat
- Mon, Nov 3$-0.13 vs $-0.01miss
- Tue, Aug 5$0.05 vs $-0.01beat
Estimates and results for MYGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MYGN officers and directors.
- Bought
- $722k
- Sold
- $101k
5 trades
2 trades
- Davis Mark Stevensold
- Kumar Rashmisold
- Bisaro Paulbought
- Raha Samraat S.bought
- Phanstiel S. Louisebought
- Phanstiel S. Louisebought
- Phanstiel S. Louisebought
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MYGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
